Search

Your search keyword '"Noguchi, Shinzaburo"' showing total 1,292 results
Start Over Author "Noguchi, Shinzaburo"
1,292 results on '"Noguchi, Shinzaburo"'

1. A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores

Author

Fujii, Takeo, Masuda, Hiroko, Cheng, Yee Chung, Yang, Fei, Sahin, Aysegul A., Naoi, Yasuto, Matsunaga, Yuki, Raghavendra, Akshara, Sinha, Arup Kumar, Fernandez, Jose Rodrigo Espinosa, James, Anjali, Yamagishi, Keisuke, Matsushima, Tomoko, Schuetz, Robert, Tripathy, Debu, Tada, Sachiyo, Jackson, Rubie S., Noguchi, Shinzaburo, Nakamura, Seigo, Acoba, Jared D., and Ueno, Naoto T.

Published
2021
Full Text
View/download PDF

8. Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From BOLERO-2

Author

Hortobagyi, Gabriel N, Chen, David, Piccart, Martine, Rugo, Hope S, Burris, Howard A, Pritchard, Kathleen I, Campone, Mario, Noguchi, Shinzaburo, Perez, Alejandra T, Deleu, Ines, Shtivelband, Mikhail, Masuda, Norikazu, Dakhil, Shaker, Anderson, Ian, Robinson, Douglas M, He, Wei, Garg, Abhishek, McDonald, E Robert, Bitter, Hans, Huang, Alan, Taran, Tetiana, Bachelot, Thomas, Lebrun, Fabienne, Lebwohl, David, and Baselga, José

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Genetics, Clinical Trials and Supportive Activities, Clinical Research, Breast Cancer, Cancer, 2.1 Biological and endogenous factors, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Aetiology, Aged, Aromatase Inhibitors, Biomarkers, Tumor, Breast Neoplasms, Everolimus, Female, Follow-Up Studies, High-Throughput Nucleotide Sequencing, Humans, Immunoenzyme Techniques, Middle Aged, Mutation, Neoplasm Invasiveness, Neoplasm Metastasis, Neoplasm Staging, Postmenopause, Prognosis, Receptor, ErbB-2, Receptors, Estrogen, Receptors, Progesterone, Survival Rate, Receptor, erbB-2, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

PurposeTo explore the genetic landscape of tumors from patients enrolled on the BOLERO-2 trial to identify potential correlations between genetic alterations and efficacy of everolimus treatment. The BOLERO-2 trial has previously demonstrated that the addition of everolimus to exemestane prolonged progression-free survival by more than twofold in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer previously treated with nonsteroidal aromatase inhibitors.Patients and methodsNext-generation sequencing was used to analyze genetic status of cancer-related genes in 302 archival tumor specimens from patients representative of the BOLERO-2 study population. Correlations between the most common somatic alterations and degree of chromosomal instability, and treatment effect of everolimus were investigated.ResultsProgression-free survival benefit with everolimus was maintained regardless of alteration status of PIK3CA, FGFR1, and CCND1 or the pathways of which they are components. However, quantitative differences in everolimus benefit were observed between patient subgroups defined by the exon-specific mutations in PIK3CA (exon 20 v 9) or by different degrees of chromosomal instability in the tumor tissues.ConclusionThe data from this exploratory analysis suggest that the efficacy of everolimus was largely independent of the most commonly altered genes or pathways in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The potential impact of chromosomal instabilities and low-frequency genetic alterations on everolimus efficacy warrants further investigation.

Published
2016

12. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.

Author

Yardley, Denise A, Noguchi, Shinzaburo, Pritchard, Kathleen I, Burris, Howard A, Baselga, José, Gnant, Michael, Hortobagyi, Gabriel N, Campone, Mario, Pistilli, Barbara, Piccart, Martine, Melichar, Bohuslav, Petrakova, Katarina, Arena, Francis P, Erdkamp, Frans, Harb, Wael A, Feng, Wentao, Cahana, Ayelet, Taran, Tetiana, Lebwohl, David, and Rugo, Hope S

Subjects
Humans, Bone Neoplasms, Breast Neoplasms, Liver Neoplasms, Lung Neoplasms, Sirolimus, Androstadienes, Receptors, Estrogen, Receptors, Progesterone, Antineoplastic Combined Chemotherapy Protocols, Disease-Free Survival, Treatment Outcome, Double-Blind Method, Postmenopause, Adult, Aged, Aged, 80 and over, Middle Aged, Female, Everolimus, Advanced breast cancer, Exemestane, Hormone receptor positive, Nonsteroidal aromatase inhibitors, Oncology, Postmenopausal, Progression-free survival, Receptors, Estrogen, Progesterone, and over, Pharmacology and Pharmaceutical Sciences, General Clinical Medicine
Abstract

IntroductionEffective treatments for hormone-receptor-positive (HR(+)) breast cancer (BC) following relapse/progression on nonsteroidal aromatase inhibitor (NSAI) therapy are needed. Initial Breast Cancer Trials of OraL EveROlimus-2 (BOLERO-2) trial data demonstrated that everolimus and exemestane significantly prolonged progression-free survival (PFS) versus placebo plus exemestane alone in this patient population.MethodsBOLERO-2 is a phase 3, double-blind, randomized, international trial comparing everolimus (10 mg/day) plus exemestane (25 mg/day) versus placebo plus exemestane in postmenopausal women with HR(+) advanced BC with recurrence/progression during or after NSAIs. The primary endpoint was PFS by local investigator review, and was confirmed by independent central radiology review. Overall survival, response rate, and clinical benefit rate were secondary endpoints.ResultsFinal study results with median 18-month follow-up show that median PFS remained significantly longer with everolimus plus exemestane versus placebo plus exemestane [investigator review: 7.8 versus 3.2 months, respectively; hazard ratio = 0.45 (95% confidence interval 0.38-0.54); log-rank P < 0.0001; central review: 11.0 versus 4.1 months, respectively; hazard ratio = 0.38 (95% confidence interval 0.31-0.48); log-rank P < 0.0001] in the overall population and in all prospectively defined subgroups, including patients with visceral metastases, [corrected] and irrespective of age. The incidence and severity of adverse events were consistent with those reported at the interim analysis and in other everolimus trials.ConclusionThe addition of everolimus to exemestane markedly prolonged PFS in patients with HR(+) advanced BC with disease recurrence/progression following prior NSAIs. These results further support the use of everolimus plus exemestane in this patient population. ClinicalTrials.gov #NCT00863655.

Published
2013

13. Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2

Author

Gnant, Michael, Baselga, Jose, Rugo, Hope S, Noguchi, Shinzaburo, Burris, Howard A, Piccart, Martine, Hortobagyi, Gabriel N, Eakle, Janice, Mukai, Hirofumi, Iwata, Hiroji, Geberth, Matthias, Hart, Lowell L, Hadji, Peyman, El-Hashimy, Mona, Rao, Shantha, Taran, Tetiana, Sahmoud, Tarek, Lebwohl, David, Campone, Mario, and Pritchard, Kathleen I

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Estrogen, Clinical Research, Cancer, Aging, Clinical Trials and Supportive Activities, Breast Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Aged, Alkaline Phosphatase, Androstadienes, Antineoplastic Agents, Aromatase Inhibitors, Bone Density, Bone Density Conservation Agents, Bone Neoplasms, Bone Remodeling, Bone Resorption, Breast Neoplasms, Collagen Type I, Confounding Factors, Epidemiologic, Disease Progression, Disease-Free Survival, Drug Administration Schedule, Everolimus, Female, Follow-Up Studies, Fractures, Spontaneous, Humans, Middle Aged, Odds Ratio, Osteogenesis, Postmenopause, Procollagen, Proportional Hazards Models, Receptors, Estrogen, Sirolimus, TOR Serine-Threonine Kinases, Treatment Failure, Treatment Outcome, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundBreast Cancer Trials of Oral Everolimus 2 (BOLERO-2), a phase III study in postmenopausal women with estrogen receptor-positive breast cancer progressing despite nonsteroidal aromatase inhibitor therapy, showed statistically significant benefits with adding everolimus to exemestane. Moreover, in preclinical studies, mammalian target of rapamycin inhibition was associated with decreased osteoclast survival and activity. Exploratory analyses in BOLERO-2 evaluated the effect of everolimus on bone marker levels and progressive disease in bone.MethodsPatients were treated with exemestane (25mg/day) and randomized (2:1) to everolimus (10mg/day; combination) or placebo (exemestane only). Exploratory endpoints included changes in bone turnover marker levels vs baseline and progressive disease in bone, defined as unequivocal progression of a preexisting bone lesion or the appearance of a new bone lesion.ResultsBaseline disease characteristics were well balanced between arms (N = 724); baseline bisphosphonate use was not (43.9% combination vs 54.0% exemestane only). At a median of 18 months of follow-up, median progression-free survival (primary endpoint) was statistically significantly longer with the combination vs exemestane only (Cox proportional hazard ratio = 0.45, 95% confidence interval = 0.38 to 0.54; log-rank, 1-sided P < .0001). Bone marker levels at 6 and 12 weeks increased with exemestane only, as expected, but decreased with the combination. The cumulative incidence rate of progressive disease in bone was lower in the combination arm. Bone-related adverse events occurred with similar frequency in both arms (3.3% combination vs 4.2% exemestane only).ConclusionThese exploratory analyses suggest that everolimus has beneficial effects on bone turnover and progressive disease in bone in patients receiving exemestane for hormone receptor-positive breast cancer progressing during/after nonsteroidal aromatase inhibitor therapy.

Published
2013

18. Induction of WT1 (Wilms' Tumor Gene)-Specific Cytotoxic T Lymphocytes by WT1 Peptide Vaccine and the Resultant Cancer Regression

Author

Oka, Yoshihiro, Tsuboi, Akihiro, Taguchi, Tetsuya, Osaki, Tadashi, Kyo, Taiichi, Nakajima, Hiroko, Elisseeva, Olga A., Oji, Yusuke, Kawakami, Manabu, Ikegame, Kazuhiro, Hosen, Naoki, Yoshihara, Satoshi, Wu, Fei, Fujiki, Fumihiro, Murakami, Masaki, Masuda, Tomoki, Nishida, Sumiyuki, Shirakata, Toshiaki, Nakatsuka, Shin-ichi, Sasaki, Ayako, Udaka, Keiko, Dohy, Hiroo, Aozasa, Katsuyuki, Noguchi, Shinzaburo, Kawase, Ichiro, Sugiyama, Haruo, and Sugimura, Takashi

Published
2004

24. Validation of the prognosis of patients with ER‑positive, HER2‑negative and node‑negative invasive breast cancer classified as low risk by Curebest™ 95GC Breast in a multi‑institutional registry study

Author

Naoi, Yasuto, primary, Tsunashima, Ryo, additional, Shimazu, Kenzo, additional, Oikawa, Masahiro, additional, Imanishi, Seiichi, additional, Koyama, Hiroshi, additional, Kamada, Yoshihiko, additional, Ishihara, Kazuhiro, additional, Suzuki, Masahiko, additional, Osako, Tomo, additional, Kinoshita, Takayuki, additional, Suto, Akihiko, additional, Nakamura, Seigo, additional, Tsuda, Hitoshi, additional, and Noguchi, Shinzaburo, additional

Published
2023
Full Text
View/download PDF

25. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial

Author

Robertson, John F R, Bondarenko, Igor M, Trishkina, Ekaterina, Dvorkin, Mikhail, Panasci, Lawrence, Manikhas, Alexey, Shparyk, Yaroslav, Cardona-Huerta, Servando, Cheung, Kwok-Leung, Philco-Salas, Manuel Jesus, Ruiz-Borrego, Manuel, Shao, Zhimin, Noguchi, Shinzaburo, Rowbottom, Jacqui, Stuart, Mary, Grinsted, Lynda M, Fazal, Mehdi, and Ellis, Matthew J

Published
2016
Full Text
View/download PDF

49. Safety and Efficacy of Everolimus With Exemestane vs. Exemestane Alone in Elderly Patients With HER2-Negative, Hormone Receptor–Positive Breast Cancer in BOLERO-2

Author

Pritchard, Kathleen I., Burris, Howard A., III, Ito, Yoshinori, Rugo, Hope S., Dakhil, Shaker, Hortobagyi, Gabriel N., Campone, Mario, Csöszi, Tibor, Baselga, José, Puttawibul, Puttisak, Piccart, Martine, Heng, Daniel, Noguchi, Shinzaburo, Srimuninnimit, Vichien, Bourgeois, Hugues, Gonzalez Martin, Antonio, Osborne, Karen, Panneerselvam, Ashok, Taran, Tetiana, Sahmoud, Tarek, and Gnant, Michael

Published
2013
Full Text
View/download PDF

50. Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: Subgroup analysis from the BOLERO-2 study

Author

Campone, Mario, Bachelot, Thomas, Gnant, Michael, Deleu, Ines, Rugo, Hope S., Pistilli, Barbara, Noguchi, Shinzaburo, Shtivelband, Mikhail, Pritchard, Kathleen I., Provencher, Louise, Burris, Howard A., III, Hart, Lowell, Melichar, Bohuslav, Hortobagyi, Gabriel N., Arena, Francis, Baselga, José, Panneerselvam, Ashok, Héniquez, Aurelia, El-Hashimyt, Mona, Taran, Tetiana, Sahmoud, Tarek, and Piccart, Martine

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results